Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimer's Disease

Author(s): Bing Gong, Samara Levine, Scott R. Barnum, Giulio M. Pasinetti

Journal Name: Current Alzheimer Research

Volume 11 , Issue 7 , 2014

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Human intravenous immunoglobulin (IVIG) has been indicated as a potential therapy for autoimmune neurological disorders, as well as in many neurodegenerative diseases, with various underlying therapeutic mechanisms such as regulation of T-cell trafficking, cytokines, Fc receptor blocking, and interruption of complement activation cascade. In Alzheimer’s disease (AD), IVIG presents naturally occurring antibodies against amyloid-beta (Aβ) aggregation, thus IVIG immunotherapy may increase the clearance of Aβ and protect brain function. Recently, we and others reported that besides Aβ clearance, IVIG specifically regulates the levels of complement-derived anaphylatoxins, such as C5a and C3, which play an important role in the regulation of AMPA and NMDA receptor expression in the brain and further upregulate the AMPA-PKA-CREB signaling pathway and synaptic function in AD mouse models. Since down-regulation of complement components has been linked with deficits of cognitive function in age-related dementia following the decline of innate immunity during aging, the IVIG immunotherapy could be an attractive novel AD therapeutic through its local regulation of C3, C5a component levels in brain.

Keywords: Alzheimer's disease, cognitive function, complement component, immunotherapy, IVIG, synaptic plasticity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 15 August, 2014
Page: [637 - 644]
Pages: 8
DOI: 10.2174/1567205011666140812113707
Price: $65

Article Metrics

PDF: 49